Insiders · VTGN

VTGN insider transactions

Vistagen Therapeutics Inc. (VTGN) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for VTGN

• 15d
  SEC Form 4 filed by Chief Medical Officer Angelov Angel S

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 15d
  SEC Form 3 filed by new insider Angelov Angel S

  3 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 54d
  SEC Form 4 filed by Tressler Nick B.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 54d
  SEC Form 4 filed by Singh Shawn

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 54d
  SEC Form 4 filed by Prince Joshua S.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 54d
  SEC Form 4 filed by Cote Elissa S.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 54d
  SEC Form 4 filed by Adler Reid G.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 148d
  Chief Operating Officer Prince Joshua S. was granted 4,386 shares, increasing direct ownership by 40% to 15,249 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 181d
  SEC Form 4 filed by Chief Financial Officer Tressler Nick B.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 181d
  SEC Form 3 filed by new insider Tressler Nick B.

  3 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 211d
  SEC Form 4 filed by Director Edick Paul R

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 211d
  SEC Form 3 filed by new insider Edick Paul R

  3 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 264d
  SEC Form 4 filed by Director Saxe Jon S

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 264d
  SEC Form 4 filed by Director Rotunno Mary L.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 264d
  SEC Form 4 filed by Director Fitzpatrick Margaret M

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 264d
  SEC Form 4 filed by Director Curley Joanne

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 264d
  SEC Form 4 filed by Director Cunningham Ann Michelle

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 337d
  Chief Operating Officer Prince Joshua S. was granted 4,882 shares, increasing direct ownership by 82% to 10,863 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 337d
  Chief Legal Officer Adler Reid G. was granted 7,541 shares, increasing direct ownership by 46% to 24,050 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 337d
  CHIEF FINANCIAL OFFICER Anderson Cynthia Lynn was granted 6,617 shares, increasing direct ownership by 107% to 12,801 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 337d
  President and CEO Singh Shawn was granted 7,541 shares, increasing direct ownership by 72% to 18,028 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 343d
  SEC Form 4 filed by Chief Corp Development Officer Cote Elissa S.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 343d
  SEC Form 3 filed by new insider Cote Elissa S.

  3 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 343d
  SEC Form 4 filed by CHIEF FINANCIAL OFFICER Anderson Cynthia Lynn

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 343d
  SEC Form 4 filed by Chief Legal Officer Adler Reid G.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 343d
  SEC Form 4 filed by Chief Operating Officer Prince Joshua S.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 343d
  SEC Form 4 filed by President and CEO Singh Shawn

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 505d
  Chief Operating Officer Prince Joshua S. was granted 3,310 shares, increasing direct ownership by 124% to 5,981 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 505d
  CHIEF FINANCIAL OFFICER Anderson Cynthia Lynn was granted 2,592 shares, increasing direct ownership by 72% to 6,184 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 631d
  SEC Form 4 filed by Director Cunningham Ann Michelle

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 631d
  SEC Form 4 filed by Director Curley Joanne

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 631d
  SEC Form 4 filed by Director Gin Jerry B

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 631d
  SEC Form 4 filed by Director Saxe Jon S

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 631d
  SEC Form 4 filed by Director Fitzpatrick Margaret M

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 631d
  SEC Form 4 filed by Director Rotunno Mary L.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 700d
  Chief Operating Officer Prince Joshua S. was granted 2,671 shares (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 701d
  CHIEF FINANCIAL OFFICER Anderson Cynthia Lynn was granted 3,592 shares (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 701d
  CHF CORP DEVEL OFF, GEN COUNS Adler Reid G. was granted 4,854 shares, increasing direct ownership by 42% to 16,509 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 701d
  CHIEF EXECUTIVE OFFICER Singh Shawn was granted 4,854 shares, increasing direct ownership by 86% to 10,487 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 706d
  SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Singh Shawn

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 706d
  SEC Form 4 filed by CHF CORP DEVEL OFF, GEN COUNS Adler Reid G.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 706d
  SEC Form 4 filed by CHIEF FINANCIAL OFFICER Anderson Cynthia Lynn

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 706d
  SEC Form 4 filed by Chief Operating Officer Prince Joshua S.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 818d
  SEC Form 4 filed by Rotunno Mary L.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 818d
  SEC Form 4 filed by Saxe Jon S

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 818d
  SEC Form 4 filed by Cunningham Ann Michelle

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 818d
  SEC Form 4 filed by Curley Joanne

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 818d
  SEC Form 4 filed by Fitzpatrick Margaret M

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 818d
  SEC Form 4 filed by Gin Jerry B

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 881d
  Adler Reid G. was granted 167 shares, increasing direct ownership by 1% to 11,655 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 881d
  Singh Shawn was granted 167 shares, increasing direct ownership by 3% to 5,633 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 942d
  SEC Form 3 filed by new insider Prince Joshua S.

  3 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 971d
  SEC Form 4 filed by Commodore Capital Lp

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 1015d
  SEC Form 4 filed by Anderson Cynthia Lynn

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 1015d
  SEC Form 3 filed by new insider Anderson Cynthia Lynn

  3 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 1029d
  SEC Form 4: Commodore Capital Lp bought $17,961,079 worth of shares (775,756 units at $23.15)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 1029d
  SEC Form 3: New insider Commodore Capital Lp claimed ownership of 799,244 shares

  3 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 1064d
  SEC Form 4 filed by Singh Shawn

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 1064d
  SEC Form 4 filed by Dotson Jerrold Duane

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 1064d
  SEC Form 4 filed by Adler Reid G.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)